The complaint filed against the NASDAQ-listed company claims that Aardvark misled the market regarding the commercial viability of its ARD-101 drug candidate. These assertions suggest that official disclosures throughout the specified class period were materially inaccurate, leaving shareholders with losses that the DJS Law Group now seeks to recover through formal litigation.
In section Releases
Aardvark Therapeutics Faces Class Action Over ARD-101 Misrepresentations
Investors who purchased Aardvark Therapeutics shares between February 13, 2025, and May 14, 2026, face an October 13, 2026, deadline to join a class action lawsuit. The litigation targets alleged federal securities law violations stemming from the company's initial public offering and subsequent public statements regarding its drug pipeline.
Shareholders do not need to serve as lead plaintiffs to participate in any potential settlement or recovery. The DJS Law Group, led by David J. Schwartz, is currently organizing the case for those who held shares during the IPO or the following 15-month window. Interested parties may contact the firm’s Eastchester, New York office to discuss their legal standing before the upcoming filing cutoff.
Comments (0)
No comments yet. Be the first!